

Supplementary tables

Supplementary table 1. Analysis of anti-EBV IgG and inflammation.

EBV IgG titers ^b	Mononuclear cell infiltrate		OR (95% CI) ^c
	Mild-Moderate ^a	Severe	
	n	n	
20.1 – 55.09	8	6	1.0
55.10 – 83.76	5	6	1.3 (0.2 – 7.3)
83.77 – 181.1	23	10	0.5 (0.1 – 2.0)
<i>p</i> for trend ^d			0.226
EBV IgG titers ^b	Polymorphonuclear cell infiltrate		OR (95% CI) ^c
	Mild-Moderate ^a	Severe	
	n	n	
20.1 – 55.09	12	2	1.0
55.10 – 83.76	10	1	0.5 (0.03 – 7.1)
83.77 – 181.1	28	5	1.2 (0.2 – 8.9)
<i>p</i> for trend ^d			0.75

^a Used as control group.

^b Units (HU/mL)

^c OR and ^d Chi square for trend, adjusted for age and sex. Also adjusted by a robust logistic regression model.

Supplementary table 2. ORs estimated after eliminating patients with intestinal metaplasia.

Serology	Healthy controls ^a	Peptic ulcer	
		Duodenal	Gastric
N (%)	129 (100)	50 (100)	12 (100)
EBV IgA			
Positives, n (%)	22 (17.1)	17 (34)	8 (66.7)**
Negatives, n (%)	107 (82.9)	33 (66)	4 (33.3)
OR ^b (95% CI)		2.3 (1.01-5.3) p = 0.048	8.4 (2.0-35.4) p = 0.003
HP IgG			
Positives, n (%)	77 (59.7)	48 (96)	7 (58.7)
Negatives, n (%)	52 (40.3)	2 (4)	5 (41.3)
OR (95% CI)		11.5 (2.6-50.8) p = 0.001	0.4 (0.1-1.8) p = 0.216
HPCagA+ IgG			
Positives, n (%)	52 (40.3)	38 (76)	3 (25)
Negatives, n (%)	77 (59.7)	12 (24)	9 (75)
OR ^b (95% CI)		4.1 (1.9-8.9) p = 0.0001	0.3 (0.08-1.1) p = 0.071

Significant differences *($p \leq 0.05$) and **($p \leq 0.001$).

^a Used as control group.

^b OR adjusted for age, sex. Also adjusted by a robust logistic regression model.